Balance Sheet Details (Tables)
|
9 Months Ended |
Sep. 30, 2024 |
|---|
| Organization, Consolidation and Presentation of Financial Statements [Abstract] |
|
| Schedule of Prepaid Expenses and Other Current Assets |
Prepaid expenses and other current assets as of September 30, 2024 and December 31, 2023 consisted of the following: | | | | | | | | | | | | | September 30,
2024 | | December 31,
2023 | | | | | | (in thousands) | | | | | | | | | | Interest receivable | $ | 17,574 | | | $ | 3,598 | | | Prepaid expenses | 10,588 | | | 6,159 | | | Purchased equipment deposits | 1,497 | | | 3,856 | | | Grant receivable | 298 | | | 9 | | | Other current assets | 3,443 | | | 2,105 | | | Total | $ | 33,400 | | | $ | 15,727 | |
|
| Schedule of Property and Equipment, Net |
Property and equipment, net as of September 30, 2024 and December 31, 2023 consisted of the following: | | | | | | | | | | | | | September 30,
2024 | | December 31,
2023 | | | | | | (in thousands) | | Furniture and equipment | $ | 1,608 | | | $ | 1,608 | | | Computers and computer software | 1,001 | | | 771 | | | Lab equipment | 31,328 | | | 25,110 | | | Leasehold improvements | 4,059 | | | 1,460 | | Manufacturing equipment | 15,390 | | | 8,134 | | Manufacturing facility and equipment construction-in-progress (1) | 123,268 | | | 51,815 | | | Total property and equipment | 176,654 | | | 88,898 | | | Less: accumulated depreciation and amortization | (13,411) | | | (9,272) | | | Property and equipment, net | $ | 163,243 | | | $ | 79,626 | |
___________(1) See Note 4, “Commercial Manufacturing and Supply Agreement,” for further details.
|
| Schedule of Other Assets, Noncurrent |
Other assets as of September 30, 2024 and December 31, 2023 consisted of the following: | | | | | | | | | | | | | September 30,
2024 | | December 31,
2023 | | | | | | (in thousands) | Manufacturing facility construction buildout (1) | $ | 57,991 | | | $ | 34,688 | | | Other long-term assets | 1,771 | | | 2,768 | | | Long-term prepaid assets | 284 | | | 106 | | | Total | $ | 60,046 | | | $ | 37,562 | |
___________(1) See Note 4, “Commercial Manufacturing and Supply Agreement,” for further details.
|
| Schedule of Accrued Expenses |
Accrued expenses as of September 30, 2024 and December 31, 2023 consisted of the following: | | | | | | | | | | | | | September 30,
2024 | | December 31,
2023 | | | | | | (in thousands) | | Other research and development | $ | 25,674 | | | $ | 30,759 | | | | | | | Other accrued expenses | 3,955 | | | 1,900 | | Clinical studies | 1,124 | | | 2,156 | | Acquired manufacturing rights (1) | — | | | 25,000 | | | Total | $ | 30,753 | | | $ | 59,815 | |
___________(1) See Note 7, “Commitments and Contingencies, Sutro Option Agreement,” for further details.
|